NUVASIVE INC appointed new CEO

Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


In connection with the consummation of the Merger and pursuant to the terms of the Merger Agreement, all of the members of the NuVasive Board immediately prior to the Effective Time ceased to be directors of NuVasive at the Effective Time and Daniel Scavilla and Keith Pfeil, each a director of Merger Sub immediately prior to the Effective Time, became a director of NuVasive. 

In connection with the consummation of the Merger and pursuant to the terms of the Merger Agreement, at the Effective Time and in connection with NuVasive becoming a subsidiary of Globus Medical: (i) J. Christopher Barry and Matthew K. Harbaugh ceased to be, respectively, the chief executive officer and the chief financial officer and principal accounting officer of NuVasive, (ii) each of Michael Farrington, Nathaniel B. Sisitsky and Dale Wolf ceased to be senior vice presidents of NuVasive, and (iii) Daniel Scavilla, Merger Sub's Chief Executive Officer immediately prior to the Effective Time, Kelly Huller, Merger Sub's Corporate Secretary immediately prior to the Effective Time, and Keith Pfeil, Merger Sub's Chief Financial Officer immediately prior to the Effective Time, became, respectively, the chief executive officer, corporate secretary and chief financial officer of NuVasive. 


-4- 


In addition, effective as of the Effective Time, the NuVasive, Inc. Deferred Compensation Plan was terminated. 

The information set forth in the Introductory Note and Item 2.01 is incorporated herein by reference into this Item 5.02.